Literature DB >> 26536058

Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer.

Takashi Matsuzuka1, Hisashi Sato2, Ryo Suzuki1, Masahiro Suzuki1, Satoshi Saijoh1, Masakazu Ikeda1, Yuta Nakaegawa1, Akiko Tani1, Mitsuyoshi Imaizumi1, Takamichi Matsui1, Yukio Nomoto1, Mika Nomoto1, Yasuhiro Tada1, Yoshiyuki Suzuki2, Koichi Omori1.   

Abstract

OBJECTIVES/HYPOTHESIS: In order to make possible organ preservation, since 2007 our hospital has performed induction chemotherapy (ICT) with cisplatin and 5-fluorouracil (PF) for hypopharyngeal cancer as chemoselection, followed by alternating chemoradiotherapy (ACRT) with docetaxel, cisplatin, and 5-fluorouracil in (TPF) good responders and curative surgery was used in poor responders.
METHODS: Twenty-six patients with stage III to stage IVB hypopharyngeal cancer received ICT. Eleven of the patients were classified as poor responders and received curative surgery. The remaining 15 patients were classified as good responders. Three of these patients underwent curative surgery, and the remaining 12 underwent ACRT.
RESULTS: The primary lesions in the 12 ACRT patients responded completely to treatment without severe late toxicities. The estimated 3-year laryngectomy-free rate for all 26 patients was 23%. The estimated 3-year overall survival rates for all 26 patients, 12 patients treated with ACRT, and 14 patients who underwent curative surgery, were 79%, 75%, and 84%, respectively.
CONCLUSION: The patients who underwent ACRT showed no significant difference in overall survival compared with the patients who underwent curative surgery. All the patients were able to proceed with this series of therapy, indicating that ICT with PF could be a feasible tool for choosing good responders. Because ACRT with TPF had a high response rate and fewer severe toxicities, this treatment could be safe and have enough impact to control hypopharyngeal cancer in good responders. LEVEL OF EVIDENCE: 4. Laryngoscope, 126:1349-1353, 2016.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Hypopharyngeal cancer; alternating chemoradiotherapy; induction chemotherapy; larynx preservation; surgery

Mesh:

Substances:

Year:  2015        PMID: 26536058     DOI: 10.1002/lary.25780

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer.

Authors:  Torahiko Nakashima; Ryuji Yasumatsu; Kaori Asai; Hideoki Uryu; Ryunosuke Kogo; Takashi Nakagawa
Journal:  Int J Clin Oncol       Date:  2017-01-06       Impact factor: 3.402

2.  To do or not to do: salvage management for hypopharyngeal cancer after chemoradiation therapy.

Authors:  Pei-Hsin Chu; Ngan-Ming Tsang; Li-Ang Lee; Chun-Ta Liao; Tuan-Jen Fang
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-20       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.